What sets Novo Holdings apart
Novo Holdings sits between an asset manager and a strategic shareholder, which shapes the work an early-career hire actually does:
- Mandate: Novo Holdings is the holding and investment company of the Novo Nordisk Foundation and the controlling shareholder of Novo Nordisk A/S and Novonesis, not a fund optimising for time-limited exit windows
- Scale: as of year-end 2025, Total Assets under Management of DKK 694 billion (EUR 93 billion), comprising the strategic Novo Group stake and a diversified Investment Portfolio of equities, bonds, real estate, infrastructure, and private equity
- Life-science specialisation across stages: dedicated teams for Seed, Venture, Growth, and Principal Investments in biotech and biopharma, alongside Planetary Health Investments and a Capital Investments arm
- Footprint: seven offices in Copenhagen (HQ), London, Boston, San Francisco, Singapore, Shanghai, and Mumbai, each weighted to its regional life-science deal flow
For a candidate weighing Novo Holdings against a generalist private equity firm or a closed-end biotech VC, the trade-off is a permanent-capital, long-horizon mandate against the carry-driven cadence of a typical fund – different incentives translate into different deal selection and different work for a junior hire.